Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy-Reference-Cited by-同舟云学术

Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy

Published:2023-09-07 Issue:1 Volume:13 Page:26-32
ISSN:2192-3183
Container-title:International Cancer Conference Journal
language:en
Short-container-title:Int Canc Conf J

Author:

Yoshimura Akihiro,Yamamoto Yoshiyuki,Nishikawa Tatsuya,Fujita Masashi,Inoue Takako,Kondo Fuki,Hayashi Takuji,Kawamura Norihiko,Nagahara Akira,Nakai Yasutomo,Nakayama Masashi,Nishimura Kazuo^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

https://link.springer.com/content/pdf/10.1007/s13691-023-00630-w.pdf

Reference22 articles.

1. Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116–1127. https://doi.org/10.1056/NEJMoa1816714

2. Motzer R, Alekseev B, Rha SY et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384:1289–1300. https://doi.org/10.1056/NEJMoa2035716

3. Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188–195. https://doi.org/10.1182/blood-2014-05-552729

4. National Cancer Institute. Common Terminology Criteria for Adverse Events v.5.0 and v.6.0 (CTCAE). Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50

5. Thompson JA, Schneider BJ, Brahmer J et al (2022) Management of immunotherapy-related toxicities, version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20:387–405. https://doi.org/10.6004/jnccn.2022.0020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Axitinib/Pembrolizumab;Reactions Weekly;2024-01-27